pHyph shows excellent medical effect with high cure rate and low risk of recurrence in bacterial vaginosis. At day 7 over 60% of patients report abscence of symtoms and at day 35, 100% are still free from BV.

News

More news

Convincing efficacy and safety results

pHyph has shown rapid symptom relief and long-term effects in clinical studies. Already on the first day of treatment, many patients experience a relief in unpleasant odor, and by day 7, it has completely disappeared in 60-70% of the patients. Treatment with pHyph shows a significantly better cure rate than the control group, and at day 35, 100% of the patients are still free from BV.

Rapid symptom relief

pHyph shows rapid effect, and by day 7, 80-90% experience noticeable symptom relief.

Day 7

At day 7, 60-70% of patients report absence of fishy smell.

Low recurrance rate

100 % of cured patients are still free from BV on day 35.

Read more about clinical results

Gedea Biotech aims to make a sustainable contribution to global women’s health and to limit the unnecessary use of antibiotics. We develop a treatment that is safe to use, effective and free of antibiotics, to solve the problem with vaginal infections and their complications.

Annette Säfholm, CEO
annette.safholm@gedeabiotech.com
+46 (0) 708 - 91 86 81

According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time. A total of nearly 3% of all antibiotics prescribed to women in Sweden are used to treat bacterial vaginosis.*

*) Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.